Oral Disintegrating Ondansetron Tablet to Reduce Vomiting From Gastroenteritis in a Pediatric Emergency Department
Primary Purpose
Gastroenteritis, Vomiting, Diarrhea
Status
Completed
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
Ondansetron Oral Disintegrating Tablet
Sponsored by
About this trial
This is an interventional prevention trial for Gastroenteritis
Eligibility Criteria
Inclusion Criteria: Acute gastroenteritis Non-bilious and non-bloody vomiting within 4 hours of triage Diarrhea Mild to moderate dehydration Exclusion Criteria: Weight less than 8 kilograms Severe dehydration Underlying disease which might affect the assessment of hydration status (e.g., chronic renal failure, hypoalbuminemia, congestive heart failure, on diuretics) History of abdominal surgery Hypersensitivity to the drug or any components in its formulation
Sites / Locations
Outcomes
Primary Outcome Measures
The proportion of children who vomit during oral rehydration therapy after receiving either 0.13-0.27 mg per kilogram of an oral disintegrating ondansetron tablet or placebo.
Secondary Outcome Measures
To compare in each treatment arm: mean number of episodes of vomiting, the proportion of children administered supplemental intravenous rehydration or requiring hospitalization.
Full Information
NCT ID
NCT00120744
First Posted
July 12, 2005
Last Updated
April 16, 2018
Sponsor
The Hospital for Sick Children
Collaborators
National Center for Research Resources (NCRR), GlaxoSmithKline, Ann & Robert H Lurie Children's Hospital of Chicago
1. Study Identification
Unique Protocol Identification Number
NCT00120744
Brief Title
Oral Disintegrating Ondansetron Tablet to Reduce Vomiting From Gastroenteritis in a Pediatric Emergency Department
Official Title
Randomized Trial of the Oral Disintegrating Ondansetron Tablet to Reduce Vomiting From Acute Gastroenteritis in a Pediatric Emergency Department
Study Type
Interventional
2. Study Status
Record Verification Date
April 2018
Overall Recruitment Status
Completed
Study Start Date
January 2004 (undefined)
Primary Completion Date
April 2005 (Actual)
Study Completion Date
April 2005 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
The Hospital for Sick Children
Collaborators
National Center for Research Resources (NCRR), GlaxoSmithKline, Ann & Robert H Lurie Children's Hospital of Chicago
4. Oversight
5. Study Description
Brief Summary
The objectives of the study were to determine whether ondansetron treatment would reduce:
the amount of vomiting in the emergency department;
the need for intravenous rehydration; and
the need for hospitalization.
Detailed Description
Background:
Vomiting may limit the success of oral rehydration in children with gastroenteritis and dehydration. Limited data suggest that while oral ondansetron may reduce vomiting from gastroenteritis, emergency department revisits may increase.
Methods:
The investigators conducted a prospective, double-blind randomized trial at a pediatric emergency department in 214 dehydrated children, aged 6 months to 10 years with gastroenteritis and mild to moderate dehydration as assessed by a dehydration score. They were randomly assigned to receive treatment with an ondansetron oral disintegrating tablet or placebo. Oral rehydration was administered according to a standard protocol. The primary outcome was the proportion of children who vomited during oral rehydration therapy. The secondary outcomes were the mean number of episodes of vomiting, and the proportion of children treated with intravenous rehydration or hospitalized.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Gastroenteritis, Vomiting, Diarrhea, Dehydration
7. Study Design
Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
Double
Allocation
Randomized
8. Arms, Groups, and Interventions
Intervention Type
Drug
Intervention Name(s)
Ondansetron Oral Disintegrating Tablet
Primary Outcome Measure Information:
Title
The proportion of children who vomit during oral rehydration therapy after receiving either 0.13-0.27 mg per kilogram of an oral disintegrating ondansetron tablet or placebo.
Secondary Outcome Measure Information:
Title
To compare in each treatment arm: mean number of episodes of vomiting, the proportion of children administered supplemental intravenous rehydration or requiring hospitalization.
10. Eligibility
Sex
All
Minimum Age & Unit of Time
6 Months
Maximum Age & Unit of Time
10 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Acute gastroenteritis
Non-bilious and non-bloody vomiting within 4 hours of triage
Diarrhea
Mild to moderate dehydration
Exclusion Criteria:
Weight less than 8 kilograms
Severe dehydration
Underlying disease which might affect the assessment of hydration status (e.g., chronic renal failure, hypoalbuminemia, congestive heart failure, on diuretics)
History of abdominal surgery
Hypersensitivity to the drug or any components in its formulation
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Stephen B Freedman, MDCM, MSCI
Organizational Affiliation
The Hospital for Sick Children
Official's Role
Principal Investigator
12. IPD Sharing Statement
Learn more about this trial
Oral Disintegrating Ondansetron Tablet to Reduce Vomiting From Gastroenteritis in a Pediatric Emergency Department
We'll reach out to this number within 24 hrs